Non-Discrimination Testing

Non-Discrimination Testing is a crucial regulatory requirement in the context of employer-sponsored 401(k) plans. These tests are designed to ensure that retirement savings benefits offered by employers do not disproportionately favor highly compensated employees over lower-income or rank-and-file employees. The purpose of these tests is to maintain fairness and compliance with the Employee Retirement Income Security Act (ERISA) and the Internal Revenue Code (IRC).

There are typically two main types of Non-Discrimination Testing:

  • Actual Deferral Percentage (ADP) Test: The ADP test assesses the elective deferrals made by eligible employees, comparing the average deferral percentage of Highly Compensated Employees (HCEs) to that of Non-Highly Compensated Employees (NHCEs). If the difference between the two groups exceeds the allowable limit, corrective actions may be required to avoid penalties and maintain the plan's qualified status.
  • Actual Contribution Percentage (ACP) Test: The ACP test evaluates employer matching contributions or employee after-tax contributions, similar to the ADP test. It ensures that employer contributions made on behalf of HCEs do not disproportionately outweigh those made for NHCEs.
  • Top-Heavy Test: In addition to ADP and ACP testing, there's also a Top-Heavy Test that examines whether the plan's key employees hold a majority of the plan's assets. If the plan is deemed top-heavy, additional contributions may be required to meet compliance standards.

Failure to pass Non-Discrimination Tests could result in the plan losing its tax-qualified status, leading to adverse tax consequences for both employers and employees. Thus, it is imperative for employers to regularly review and administer these tests to ensure fair and equitable distribution of retirement benefits among their workforce.



Next Up

Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.
Most U.S. employers now offer paid maternity leave beyond the legal minimum, but coverage varies widely once you look past the basics. According to Mployer Insights' 2026 analysis of more than 50,000 employer benefit plans, 68% of employers provide paid maternity leave on top of short-term disability, typically adding 8 extra weeks, and half now cover 100% of salary during the disability period. Support drops off from there: only 41% of employers offer paid bonding leave for non-birth parents, and advanced family-building benefits remain even less common, with just 28% covering IVF and 11% offering adoption financial assistance. The data suggests that while baseline maternity leave has become standard, more comprehensive family-building support is still the exception rather than the norm.